Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleos...

Full description

Saved in:
Bibliographic Details
Main Authors: Catherine Orrell, Franco Felizarta, André Nell, Thomas N. Kakuda, Ludo Lavreys, Steven Nijs, Lotke Tambuyzer, Rodica Van Solingen-Ristea, Frank L. Tomaka
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:AIDS Research and Treatment
Online Access:http://dx.doi.org/10.1155/2015/938628
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1155/2015/938628

Similar Items